Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)Benjamin Hanfstein, Susanne Schnittger, Claudia Haferlach et al.|Leukemia|2012Cited by 417
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsRoland J. Fuchs, Rüdiger Hehlmann, Michael Lauseker et al.|Leukemia|2017Cited by 339
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IVRüdiger Hehlmann, Andreas Hochhaus, Martin C. Müller et al.|Journal of Clinical Oncology|2013Cited by 299
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVAlice Fabarius, Armin Leitner, Andreas Hochhaus et al.|Blood|2011Cited by 289
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IVLida Kalmanti, Susanne Saußele, Michael Lauseker et al.|Leukemia|2015Cited by 274